How Turkey’s 2026 Pharmaceutical Pricing Policy Transformation Impacts Foreign Firms

Introduction

Turkey has long been a strategic market for global pharmaceutical companies, but its pricing policies have often posed challenges. In 2026, the Turkish government introduced significant revisions to its pharmaceutical pricing framework, directly impacting foreign firms operating in the country. This article provides a comprehensive analysis of how Turkey’s pharmaceutical pricing policy has changed for foreign firms in 2026, covering reference pricing mechanisms, currency adjustments, market access requirements, and strategic implications. Understanding these changes is crucial for multinational companies looking to maintain or expand their presence in Turkey’s dynamic healthcare market.

Overview of Turkey’s Pharmaceutical Pricing Policy

Turkey’s pharmaceutical pricing is primarily governed by the Reference Pricing System, which aligns domestic prices with those in a basket of European Union countries. Historically, this system has aimed to control healthcare expenditures while ensuring patient access to medicines. However, frequent devaluation of the Turkish lira and inflation have strained the balance between affordability and profitability for foreign firms. The 2026 policy changes represent a significant shift in how prices are determined and adjusted.

Key Elements of the Pre-2026 Framework

• Reference basket: Prices were benchmarked against five EU countries (France, Italy, Spain, Portugal, Greece).
• Exchange rate: The Turkish lira exchange rate used for conversion was updated quarterly, often lagging behind market rates.
• Price reductions: Mandatory discounts of up to 41% for patented medicines and even higher for generics.
• Reimbursement list: Products had to be listed on the Social Security Institution (SGK) reimbursement list to gain market access.

These elements created a challenging environment for foreign firms, leading to delayed launches, product withdrawals, and reduced investment in innovative therapies.

Major Changes in 2026 Pricing Policy

The 2026 policy overhaul introduces several key modifications that directly affect foreign pharmaceutical companies. These changes aim to improve predictability, incentivize innovation, and align pricing with economic realities.

1. Updated Reference Basket and Calculation Method

The reference basket has been expanded from five to seven countries, adding Poland and Hungary. These Central European markets have lower price levels than Western EU countries, potentially lowering the reference price ceiling. However, the calculation method now uses a weighted average instead of the lowest price, which may mitigate some downward pressure. Foreign firms must reassess their pricing strategies for Turkey based on this new mix.

2. More Frequent Exchange Rate Adjustments

Previously, the exchange rate used for converting reference prices was updated quarterly, often causing significant lag. In 2026, the Turkish Ministry of Health will update the exchange rate monthly based on the average rate of the previous month. This change reduces the risk of sudden price erosion due to lira depreciation, providing more stability for foreign firms when planning revenue projections.

3. Introduction of a Currency Adjustment Coefficient

To further protect against inflation, a new currency adjustment coefficient has been introduced. This coefficient is applied to the reference price before conversion, effectively increasing the base price. The coefficient is calculated using a formula that accounts for the difference between the official inflation rate and the depreciation rate of the lira. For foreign firms, this means higher potential ex-factory prices, though the exact impact depends on the coefficient’s value, which will be announced quarterly.

4. Revised Discount Structure for Innovative Medicines

One of the most significant changes is the reduction in mandatory discounts for innovative medicines (new chemical entities with proven therapeutic value). The maximum discount has been lowered from 41% to 33% for products that receive a positive Health Technology Assessment (HTA) from the Turkish Medicines and Medical Devices Agency (TITCK). This creates a clearer pathway for premium pricing of novel therapies, encouraging foreign firms to launch innovative products in Turkey.

5. Streamlined Market Access and Reimbursement Process

The 2026 policy introduces a fast-track reimbursement pathway for medicines that address unmet medical needs or are designated as orphan drugs. The evaluation timeline has been reduced from 360 days to 180 days. Additionally, the SGK now accepts electronic submissions, reducing administrative burdens. Foreign firms can expect quicker decisions on pricing and reimbursement, improving time-to-market.

Impact on Foreign Firms

The 2026 changes have both positive and negative implications for foreign pharmaceutical companies. Below is a breakdown of the key effects.

Positive Impacts

• Improved pricing predictability: Monthly exchange rate updates and the currency adjustment coefficient reduce volatility, allowing better financial planning.
• Higher potential prices for innovative drugs: Lower mandatory discounts and the possibility of premium pricing for HTA-approved products incentivize R&D investment.
• Faster market access: The fast-track pathway for priority medicines shortens the time from regulatory approval to reimbursement.
• Expanded reference basket: Inclusion of lower-price countries may be offset by the weighted average calculation, but firms can now benchmark against a more diverse set of markets.

Challenges and Risks

• Continued pressure on generics: The discount structure for generics remains unchanged at up to 50%, squeezing margins for off-patent products.
• Uncertainty around the coefficient: The exact formula for the currency adjustment coefficient is not fully transparent, creating some risk.
• HTA requirements: To benefit from lower discounts, firms must invest in local health technology assessments, which can be costly and time-consuming.
• Competitive dynamics: Local manufacturers may still undercut foreign firms on price, especially for generics.

Strategic Recommendations for Foreign Firms

To navigate the 2026 landscape successfully, foreign pharmaceutical companies should consider the following strategies:

• Prioritize innovative pipelines: Focus on launching new, differentiated therapies that can qualify for the reduced discount rate and fast-track reimbursement.
• Strengthen local HTA capabilities: Invest in health economics and outcomes research (HEOR) to demonstrate value and secure favorable pricing.
• Optimize currency risk management: Use financial instruments like forward contracts to hedge against lira volatility, complementing the policy’s monthly adjustments.
• Engage with regulators early: Proactive dialogue with TITCK and SGK can help shape the interpretation of new rules and expedite approvals.
• Review portfolio pricing: Reassess pricing for existing products in light of the new reference basket and coefficient to ensure competitiveness and profitability.

Conclusion

Turkey’s 2026 pharmaceutical pricing policy represents a significant evolution aimed at balancing cost control with the need to attract foreign investment in innovative medicines. For foreign firms, the changes offer greater predictability, potential for higher prices on novel therapies, and faster market access. However, challenges remain, particularly for generic products and in navigating the new HTA requirements. By adapting their strategies to focus on innovation, local evidence generation, and proactive engagement, foreign pharmaceutical companies can turn these policy shifts into a competitive advantage. Understanding how Turkey’s pharmaceutical pricing policy has changed for foreign firms in 2026 is essential for anyone looking to succeed in this critical market.